Just about everyone by now knows how the drug industry works
to poison the minds of American doctors—not that many of them have
resisted drinking the Kool-Aid, which comes in the form of ego-tripping
awards, junkets, dinners, research funding, and cash in exchange for endorsing
or prescribing the most lucrative drugs. But even against this backdrop of
sleaze, the latest news on the ties between Big Pharma and Big Psych
could take your breath away.
It turns out that not just some, but most of the shrinks who wrote the American Psychiatric Association’s most recent clinical guidelines for treating depression, bipolar disorders, and schizophrenia—which together account for $25 billion in prescription drug sales annually—had financial ties to drug companies, according a study to be published in Psychotherapy and Psychosomatics, as reported in the Boston Globe.
Summarizing the findings, which were compiled by researchers largely from public records, the Kaiser Daily Health Policy Report states:
According to the study, 18 of the 20 authors of the guidelines had at least one financial tie to drug companies. Twelve authors had ties in at least three categories, such as consulting, research grants, speaking fees or stock ownership, the study found. In addition, the study found that all of the authors of schizophrenia and bipolar guidelines had relationships with the drug industry, while 60% of the authors of the depression guidelines had such connections. According to the study, more than 75% of the authors received funding for research from drug companies. In addition, one-third of the authors served on the speakers’ bureaus of drug companies, the study shows.